No Prescription |
 |
 | ||
|
DUOVIR Combivir |
|
| ||
No Prescription » Prescription Drugs 6 » DUOVIR Combivir The combination of lamivudine and zidovudine is used to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Lamivudine and zidovudine are in a class of antiviral medications called synthetic nucleoside analogues. They work by slowing the spread of HIV infection in the body. Lamivudine and zidovudine is not a cure and may not decrease the number of HIV-related illnesses. Lamivudine and zidovudine does not prevent the spread of HIV to other people.The combination of lamivudine and zidovudine comes as a tablet to take by mouth. It is usually taken twice a day with or without food. To help you remember to take this medication take it around the same time every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take this medication exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Buy DUOVIR Combivir and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About DUOVIR Combivir: Product Type: Prescription Drugs 6 DUOVIR ( Combivir Generic Lamivudine/Zidovudine ) DUOVIR (Combivir Generic Lamivudine/Zidovudine) Combivir Generic Lamivudine/Zidovudine 300mg/150mg Tabs 30 (3 x 10) 60 Tablets 2 x 60 Tablets 4 x 60 Tablets Combivir Generic Lamivudine/Zidovudine DUOVIR
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
